RARE - Ultragenyx sees 2023 product revenue of $425M-$450M

• Ultragenyx Pharmaceutical ( NASDAQ: RARE ) on Friday said it sees total product revenue of $425M-$450M in 2023 with the vast majority of it -- $325M-$340M -- coming from Crysvita (burosumab).
• The rare diseases focused biotech also sees preliminary 2022 product revenues of $352M-$356M.
• The consensus revenue estimate for 2022 is $360.21M. For 2023, it is $444.66M.
• Ultragenyx ( RARE ) said it ended 2022 with a cash balance of ~$900M.
• Crysvita is an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia.
• Read why Seeking Alpha contributor Avisol Capital Partners rates Ultragenyx ( RARE ) a hold.

For further details see: